Mesoblast (NASDAQ:MESO) Sets New 52-Week High – Time to Buy?

Shares of Mesoblast Limited (NASDAQ:MESO) hit a new 52-week high during trading on Tuesday . The company traded as high as $12.19 and last traded at $11.95, with a volume of 374585 shares. The stock had previously closed at $11.72.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on MESO shares. Jefferies Financial Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating in a research note on Thursday, August 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Tuesday, September 24th. Finally, StockNews.com lowered shares of Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, Mesoblast currently has an average rating of “Moderate Buy” and an average price target of $11.50.

Mesoblast Stock Up 2.0 %

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The business’s 50-day moving average is $9.57 and its two-hundred day moving average is $7.87.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC grew its position in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after purchasing an additional 26,959 shares during the last quarter. XY Capital Ltd bought a new position in Mesoblast in the 3rd quarter worth about $244,000. Signaturefd LLC grew its position in Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares during the last quarter. Creative Planning bought a new position in Mesoblast in the 3rd quarter worth about $147,000. Finally, Perkins Coie Trust Co grew its position in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after purchasing an additional 1,500 shares during the last quarter. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.